- Home
- APLT vs PAVS Comparison
APLT vs PAVS Comparison
Compare APLT & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- PAVS
- Stock Information
- Founded
- APLT 2016
- PAVS 2004
- Country
- APLT United States
- PAVS United States
- Employees
- APLT N/A
- PAVS N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- PAVS Medicinal Chemicals and Botanical Products
- Sector
- APLT Health Care
- PAVS Health Care
- Exchange
- APLT Nasdaq
- PAVS Nasdaq
- Market Cap
- APLT 37.5M
- PAVS 89.6M
- IPO Year
- APLT 2019
- PAVS 2019
- Fundamental
- Price
- APLT $0.41
- PAVS $1.06
- Analyst Decision
- APLT Buy
- PAVS
- Analyst Count
- APLT 7
- PAVS 0
- Target Price
- APLT $6.10
- PAVS N/A
- AVG Volume (30 Days)
- APLT 1.9M
- PAVS 27.2K
- Earning Date
- APLT 05-20-2025
- PAVS 01-01-0001
- Dividend Yield
- APLT N/A
- PAVS N/A
- EPS Growth
- APLT N/A
- PAVS N/A
- EPS
- APLT N/A
- PAVS N/A
- Revenue
- APLT $455,000.00
- PAVS $6,613,273.00
- Revenue This Year
- APLT $1,768.13
- PAVS N/A
- Revenue Next Year
- APLT $361.28
- PAVS N/A
- P/E Ratio
- APLT N/A
- PAVS N/A
- Revenue Growth
- APLT N/A
- PAVS 2.50
- 52 Week Low
- APLT $0.30
- PAVS $0.32
- 52 Week High
- APLT $10.62
- PAVS $1.50
- Technical
- Relative Strength Index (RSI)
- APLT 48.67
- PAVS 19.30
- Support Level
- APLT $0.39
- PAVS $1.22
- Resistance Level
- APLT $0.49
- PAVS $1.40
- Average True Range (ATR)
- APLT 0.04
- PAVS 0.06
- MACD
- APLT 0.01
- PAVS -0.03
- Stochastic Oscillator
- APLT 55.40
- PAVS 0.00
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.